ESMO26: Sac-TMT sets survival benchmark in recurrent endometrial cancer
Following progression on platinum-based chemotherapy and immunotherapy, patients with advanced or recurrent endometrial cancer (EC) face limited treatment options. The …
Post
-
-
Pfizer’s prostate cancer combo moves to earlier line on expanded US approval
The US Food and Drug Administration (FDA) has awarded a label expansion to Pfizer’s targeted oncology combination of Talzenna (talazoparib) …
-
Regeneron agrees to $270m extension to supply Ebola medicine in US
Regeneron Pharmaceuticals has agreed to a nearly $270m contract extension to supply its Ebola therapy, Inmazeb, to the US Government …
-
China’s NMPA accepts Innovent application for sintilimab combo
Innovent Biologics has received acceptance from China's National Medical Products Administration (NMPA) to review its sintilimab and Nolgileucel injection (GC101) …
-
ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction
Results of two Phase III trials, SANOVO and SAFFRON, with HUTCHMED and AstraZeneca’s Orpathys (savolitinib) were presented recently at the …
-
Transitioning from lab bench to GMP: What research scientists should know about manual aseptic filling
Many breakthrough therapies originate in research labs: academic institutions, biotech startups, and translational centers. The research-grade environments in which these …
-
Lunit and Summit to evaluate pathology platform for tumour analysis
Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing …
-
Pathos AI completes $237m Series E round to expand oncology pipeline
Pathos AI has secured $237m in a Series E financing round to expand its clinical oncology pipeline and scale its …
-
UK biotech poised for record VC year after maintaining recovery momentum
A new report released by the BioIndustry Association (BIA) has found that the UK is likely on track to post …
-
ESMO26: Bayer’s Phase III Nubeqa win leaves survival and abiraterone questions open
Approximately 15% of men with very high-risk prostate cancer develop incurable distant metastases within five years of definitive treatment. Standard …
-
ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer
For GSK’s mocertatug rezetecan (Mo-Rez), the tumour microenvironment may predict response better than the target itself. B7-H4 has emerged as …
-
ESMO26: Oral cell cycle inhibitors place Cyclin E1 as new target in PROC
Cyclin E1 is emerging as a promising therapeutic target in platinum-resistant ovarian cancer (PROC), where conventional single-agent non-platinum chemotherapy has …
-
US targets Chinese biotech investment, but licensing deals remain exempt
The US government is seeking to curb American investment in Chinese firms involved in advanced drug development after adding the …
-
Egypt reforms obsolete pharmaceutical pricing framework
After nearly 15 years, Egypt’s pharmaceutical pricing framework has entered a new phase. In late September 2026, the Egyptian Drug …
-
Gilead spends $1.28bn on PepStar’s potential Icotyde rival
Gilead Sciences has inked a billion-dollar deal with Shanghai-based PepStar therapeutics to secure the global rights to an oral IL-23 …
